Roche and Nurix announce $700 million-upfront BTK degrader deal worth up to $2.3 billion
On June 8, 2026, Roche and Nurix Therapeutics announced an exclusive global licensing and collaboration agreement to co-develop and co-commercialize bexobrutideg (NX-5948), an investigational oral Bruton’s tyrosine kinase (BTK) degrader, across malignant hematology, immunology, and neurology. Nurix will receive $700 million upfront and is eligible for development, regulatory, and sales milestones representing potential total payments of up to $2.3 billion. Development costs will be shared 40% by Nurix and 60% by Roche, with equal U.S. profit-and-loss sharing and royalties to Nurix on ex-U.S. sales.
Primary source material identifies June 8, 2026 as the announcement date for an exclusive Roche–Nurix licensing and collaboration agreement, with $700 million in upfront cash, potential total payments of up to $2.3 billion, and a 40%/60% development-cost split. The September 14 timestamp belongs to a later AI-generated summary rather than the underlying real-world announcement, so the occurrence time is reset to the earliest dated release record, 05:00 UTC; the exact hour is not independently stated. This is a material, forward-looking corporate action affecting Nurix’s financing and development outlook and Roche’s pipeline, while the caveated AI summary’s claims about clinical data are not relied upon. Stakeholder approval is limited to the two direct counterparties and the most clearly evidenced direct competitive exposures: BeiGene’s competing BTK degrader and Lilly’s pirtobrutinib comparator; potential CRO, laboratory, and more remote legacy-therapy effects are too speculative or indirect.
A landmark Roche partnership expands the clinical and commercial reach of a BTK degrader, with $700M upfront and up to $2.3B in milestones.